Genmab initiates phase III trial with drug against cervical cancer

Positive phase II results prompt Genmab and its collaborative partner Seattle Genetics to submit a US registration application for accelerated approval, which is given to drugs that accommodate an unmet need for the treatment of serious illnesses.
Photo: Joost Melis / Genmab / PR
Photo: Joost Melis / Genmab / PR

The biotech firm Genmab will be initiating a phase III trial program with Tisotumab Vedotin for the treatment of cervical cancer with the aim of assessing its efficiency compared with chemotherapy for patients with recurrent or metastatic cervical cancer, according to a Genmab statement on Monday evening.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading